124 results
8-K/A
EX-99.1
LAB
Standard BioTools Inc.
19 Jan 24
Financial Statements and Exhibits
4:33pm
Innovation Accelerator (“AVIA”), to provide services related to expanding our contractual relationships with health system providers. The Consulting
8-K
EX-99.2
LAB
Standard BioTools Inc.
8 Jan 24
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
8:39am
Differentiated technology Scientific brilliance focused on innovation, partnership, and power of proteomics Strong 2023 Progress(1) ~20% core revenue
425
EX-99.1
SLGCW
SomaLogic, Inc.
19 Dec 23
Business combination disclosure
4:47pm
technology Scientific brilliance focused on innovation, partnership, and power of proteomics (1) Reflects SomaLogic’s performance through the 3
8-K
EX-99.1
LAB
Standard BioTools Inc.
19 Dec 23
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023
4:45pm
technology Scientific brilliance focused on innovation, partnership, and power of proteomics (1) Reflects SomaLogic’s performance through the 3
425
EX-99.1
rjqtbtvxn9y4l
28 Nov 23
Business combination disclosure
9:11pm
8-K
EX-99.1
96ksky 3j
28 Nov 23
Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023
9:09pm
425
EX-99.2
tlgln za7
4 Oct 23
Business combination disclosure
8:13am
8-K
EX-99.2
5kp2r9 xci3j1
4 Oct 23
Standard BioTools and SomaLogic to Combine in All-Stock Merger
8:08am
8-K
EX-99.1
reww1oj022q
5 May 22
Standard BioTools Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
dcg lolmppm
5 Apr 22
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
5:07pm
8-K
EX-99.2
urrrye7x856mkqc4ez
5 Apr 22
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
5:07pm
8-K
EX-99.1
k1bwb70spqe 877gyu
28 Mar 22
Provides Stockholders Additional Time to Consider $250 Million Strategic Capital
6:10am
DEFA14A
4flds44i
21 Mar 22
Additional proxy soliciting materials
6:05am
DEFA14A
oc44zj rx8
18 Mar 22
Additional proxy soliciting materials
6:04am